

Therapeutic Update



ESCAPE Bio Inc., a precision neurology company developing targeted therapies for genetic forms of neurodegenerative diseases, is rapidly progressing a new therapeutic (ESB1609) through early clinical trials. ESB1609 is orally available, brain-penetrant, and works through a novel mechanism. Data from preclinical studies presented at the Lysosomal WORLD conference this year demonstrates the ability of the drug to induce proteins that can redistribute cholesterol and certain other lipids which become stored in the brain in NPC animal models. More info can be found at www.ESCAPEbio.com.

www.ESCAPEbio.com